Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16023—Virus like particles [VLP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
  • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
  • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

• CD8 CTL that kill HIV-infected cells and antibodies that broadly neutralise HIV primary isolates might be protective anti-HIV immune responses in uninfected individuals who are subsequently exposed to
• a nucleic acid molecule comprising a modified HIV genome devoid of long terminal repeats and wherein vpr and ta t sequences are functionally disabled and a constitutive promoter operatively connected to the modified HIV genome for constitutive expression of the modified genome to produce non-infectious, non-replicating and immunogenic HIV-like particles.
• Figure 1 contains the human cytomegalovirus (CMV) promoter and enhancer element as well as CMV Intron A sequences in place of the MT promoter.
• the coding sequences for the regulatory proteins Tat and Vpr were modified to prevent synthesis of both proteins upon expression.
• the signal peptide fragment of HIV-1 gpl20 was replaced by the signal peptide fragment of the glycoprotein D (gD) of Herpes Simplex Virus (HSV) .
• the G418 resistance gene was co-linearly inserted into the plasmid and placed under the regulation of the SV40 promoter and polyadenylation sequences .
• Figure 3 shows Western blot analysis of HIV virus-like particles expressed from a Vero cell line containing the expression vector pCMVgDtat ' vpr " (clone Vero-356) which was established after stable transfection of Vero cells.
• the Western blot analysis shows the continued stable production of HIV-like particles with increasing passage number, panels A (passages 14 to 18) and B
• the HIV-like particle may contain other env gene products, particularly those from clinical isolates from HIV-1 infected patients, such as a primary HIV-1 isolate from clades A, B, C, D, E and 0, including the specific isolate Bx08.
• the env gene products also may be a chimer of the gpl20 protein from one source and the gp41 from another source, such as MN/LAI, Bx08/LAI and clades/LAI chimers.
• the plasmid pCMVgDtat ' vpr " may be stably transfected into monkey kidney Vero cells or other mammalian cells by any convenient procedure for expression of non-infectious, non-replicating immunogenic HIV-like particles therefrom.
• G418 resistance cell lines are cloned and screened for production of the particles in the culture supernatant by measuring the amount of particle-associated Gag p24 protein using a suitable antibody. Such a screening procedure is described in the aforementioned US Patents Nos. 5,439,809 and 5,571,712.
• the levels of expression of the HIV-like particle may be increased by induction using sodium butyrate with or without dexamethasone, as seen from Example 3 and Figure 3, panel C.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Virology (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Public Health (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• AIDS & HIV (AREA)
• Veterinary Medicine (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Saccharide Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=25537545

Family Applications (1)

Country Status (12)

Cited By (5)

Families Citing this family (13)

Family Cites Families (12)

• 1997
  • 1997-12-16 US US08/991,773 patent/US6121021A/en not_active Expired - Lifetime
• 1998
  • 1998-12-14 US US09/555,834 patent/US6572863B1/en not_active Expired - Fee Related
  • 1998-12-14 CA CA002312943A patent/CA2312943C/en not_active Expired - Fee Related
  • 1998-12-14 WO PCT/CA1998/001164 patent/WO1999031250A2/en not_active Ceased
  • 1998-12-14 DE DE69833686T patent/DE69833686T2/de not_active Expired - Lifetime
  • 1998-12-14 BR BR9813626-7A patent/BR9813626A/pt not_active Application Discontinuation
  • 1998-12-14 PT PT98960976T patent/PT1038001E/pt unknown
  • 1998-12-14 EP EP98960976A patent/EP1038001B8/en not_active Expired - Lifetime
  • 1998-12-14 AT AT98960976T patent/ATE318909T1/de active
  • 1998-12-14 JP JP2000539149A patent/JP2004509601A/ja active Pending
  • 1998-12-14 ES ES98960976T patent/ES2262250T3/es not_active Expired - Lifetime
  • 1998-12-14 AU AU16577/99A patent/AU749174B2/en not_active Ceased
  • 1998-12-14 DK DK98960976T patent/DK1038001T3/da active

Also Published As

Similar Documents

Legal Events